Selumetinib
- Generic Name
- Selumetinib
- Brand Names
- Koselugo
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15BrClFN4O3
- CAS Number
- 606143-52-6
- Unique Ingredient Identifier
- 6UH91I579U
- Background
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.
...
- Indication
Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients ≥2 years who have symptomatic, inoperable plexiform neurofibromas (PN).
- Associated Conditions
- Neurofibromatosis, type 1 (von Recklinghausen's disease)
- Associated Therapies
- -
No news found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath